726 filings
8-K
APTO
Aptose Biosciences Inc
31 May 24
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
8:05am
DEF 14A
APTO
Aptose Biosciences Inc
Definitive proxy
15 May 24
11:47am
10-Q
2024 Q1
APTO
Aptose Biosciences Inc
Quarterly report
14 May 24
5:06pm
8-K
APTO
Aptose Biosciences Inc
14 May 24
Aptose Reports Results for the First Quarter 2024
4:15pm
8-K
APTO
Aptose Biosciences Inc
6 May 24
Regulation FD Disclosure
4:45pm
8-K
bjjqhce0xb m1l07jl2
1 May 24
Entry into a Material Definitive Agreement
4:30pm
8-K
gz74j7m
26 Apr 24
Entry into a Material Definitive Agreement
7:30am
8-K
bzud90g1ekcftei1ym
5 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:05pm
8-K
h6gu95qodgn8s
26 Mar 24
Aptose Reports Results for the Fourth Quarter and Full Year 2023
4:04pm
8-K
q9h8c4m4
18 Mar 24
Regulation FD Disclosure
4:45pm
8-K
2iut 9supslo
1 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
zcwz pgw4aom3gykn
31 Jan 24
Regulation FD Disclosure
4:02pm
8-K
7dj957xh
29 Jan 24
Entry into a Material Definitive Agreement
9:44pm
424B4
f0ktwqe39qqk847
26 Jan 24
Prospectus supplement with pricing info
5:30pm
8-K
xx8zjyfq2iou
26 Jan 24
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
8:00am
EFFECT
t8fc 190evir
26 Jan 24
Notice of effectiveness
12:15am
S-1MEF
s4o5 9tzrkb
25 Jan 24
Registration of additional securities for an S-1
9:44pm